Desenvolvimento e importância das vacinas: por que ainda é preciso afirmar o óbvio?
DOI:
https://doi.org/10.34119/bjhrv6n4-187Keywords:
vacinas, negacionismo, COVID-19Abstract
As vacinas são cruciais na prevenção de doenças e representam uma estratégia coletiva de saúde pública. Elas possuem um histórico de sucesso desde a luta contra a varíola no século XVIII. Com o tempo foram desenvolvidas as vacinas clássicas e vacinas modernas decorrentes da aplicação da bioengenharia. Apesar da eficácia, o negacionismo tem ameaçado as estratégias de imunização. A pandemia do SARS-CoV-2, mesmo diante de ideologias contraditórias, destacou a importância das vacinas e do progresso da construção desses imunizantes para uma rápida prevenção. Dados de muitos países mostraram que a vacinação em massa foi essencial para controlar a COVID-19 e manter a cobertura de proteção. Além da prevenção, reduz a propagação de patógenos e contribui para a imunidade coletiva. Até o presente momento, as metodologias foram eficazes e com benefícios comprovados para a saúde pública. Em suma, as evidências corroboraram através do tempo mostrando que as vacinas são essenciais e a aplicação em larga escala é uma estratégia coletiva importante para proteger a população de diversos agravos.
References
ANDRE, F. et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bulletin of the World Health Organization, v. 98, n. 2, p. 146–148, Fev. 2020.
BBC. Vacinas contra covid: como está a vacinação no Brasil e no mundo. BBC News, 2023. Disponível em: https://www.bbc.com/portuguese/internacional-56024504. Acesso em: 28 jun. 2023.
BERKOWITZ, N. et al. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. New England Journal of Medicine, v. 386, n. 4, e98, 2022. Disponível em: https://doi.org/10.1056/NEJMc2236739. Acesso em: 18 fev. 2022.
BERTOZZI, S. et al. Vaccines: from basic science to clinical trials - a comprehensive review. AIMS Microbiology, v. 6, n. 1, p. 1-30, 2020.
CAMPE, A. et al. Historical and Clinical Aspects of Vaccine Development. Viral Immunology, v. 32, n. 8, p. 400-411, 2019.
CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC). Types of Vaccines. Disponível em: https://www.cdc.gov/vaccines/vpd/vaccines-types.html. Acesso em: 24 de junho de 2021.
CENTERS FOR DISEASE CONTROL AND PREVENTION. Vaccine Safety. Disponível em: https://www.cdc.gov/vaccinesafety/concerns/antivaccinemovement.html. Acesso em: 03 de setembro de 2021.
CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC). Vaccines and Immunizations. Disponível em: https://www.cdc.gov/vaccines/index.html. Acesso em: 02 jul. 2021.
CHEN, X. et al. Safety of COVID-19 Vaccines: A Systematic Review and Network Meta-Analysis of 338 779 Participants from Randomized Controlled Trials. medRxiv, jul. 2021. DOI: 10.1101/2021.07.13.21260436.
CHOPRA, M.; BANERJEE, S. K.; KUMBHAR, B. S. Epidemiology and Control of Poliomyelitis: Indian Perspective. Indian Journal of Community Medicine, v. 34, n. 2, p. 83–89, 2009.
CROTEAU, R. J. et al. Social listening insights on vaccine hesitancy during COVID-19. Health Promotion International, v. 35, n. 5, p. 1199–1203, out. 2020. DOI: 10.1093/heapro/daaa096.
DAWSON, N. A. J. et al. Plasmid DNA vaccines: a review of their manufacturing and quality control. Expert Opinion on Biological Therapy, v. 20, n. 6, p. 611-623, 2020.
DWYER, C. et al. Science Communications Strategies for Overcoming COVID-19 Vaccine Hesitancy. Frontiers in Psychology, v. 12, abr. 2021. DOI: 10.3389/fpsyg.2021.672101.
EISENHAUER, M. J. et al. Subunit Vaccines in the Battle Against COVID-19 Pandemic: Current Strategies and Challenges. Vaccines, v. 10, n. 2, p. 263, 2022.
EL SEBSY, R. et al. New vaccine technologies in the COVID-19 pandemic era. Human vaccines & immunotherapeutics, v. 17, n. 1, p. 168-173, 2021.
FEINSTEIN, A. R. The History of Vaccines and Immunization: Familiar Patterns, New Challenges. Health Affairs, v. 30, n. 6, p. 1043-1050, 2011.
FREIRE, M. S. et al. Vaccines: State of the art and future perspectives. Journal of microscopical and ultrastructural pathology, v. 6, n. 3, p. 79-85, 2022.
GORNITZKI, C. et al. Safety, immunogenicity and effectiveness of the variant and novel COVID-19 vaccines: A systematic review and meta-analysis. Journal of Infection, v. 82, n. 3, p. e2-e22, 2021.
HARRISON, A.; WHEELER, K. The History of Immunizations for Children: Exploring the Past and Future of Vaccines. Journal of Pediatric Nursing, v. 56, p. 45-54, 2021.
JUNQUEIRA-KIPNIS, A. P. et al. Bacterial vaccines: the immunology behind their mechanisms of action, safety, and efficacy. Mediators of Inflammation, v. 2018, 2018.
KENNEDY, R. B. et al. The science behind the vaccines that will save the world. Nature, v. 589, n. 7841, p. 27-29, 2019.
KRAMMER, F. et al. Advances in the Development of mRNA-Based Vaccines. Expert Review of Vaccines, v. 18, n. 12, p. 1333-1344, 2020.
KRAMMER, F. Options for further improving the safety, efficacy, and durability of COVID-19 vaccines. Cell Reports Medicine, v. 1, n. 2, p. 100015, 2020.
KRAUSE, P. R. et al. Developing COVID-19 Vaccines at Pandemic Speed. New England Journal of Medicine, v. 382, n. 21, p. 1969-1973, 2020.
LARSEN, R. J. L. et al. Vaccine Hesitancy: The Next Challenge in the Fight Against COVID-19. Eur J Clin Invest, v. 51, n. 4, mar. 2021. DOI: 10.1111/eci.13406.
LARSON, H. J. et al. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012. Vaccine, v. 34, n. 41, p. 4860–4869, 2016. Disponível em: https://doi.org/10.1016/j.vaccine.2016.08.083. Acesso em: 03 de setembro de 2021.
LI, X. et al. Current status of preclinical and clinical trials for mRNA vaccines against COVID-19 in the world. BioScience Trends, v. 16, n. 6, p. 339-348, 2022.
MARRIOTT, A.; WHITING, S. History and Progress of Vaccination. Clinical Infectious Diseases, v. 67, n. 3, p. 511-518, 2018.
MAYADAS, T. et al. RNA vaccines: an innovative and emerging approach to prevent COVID-19. Journal of Clinical & Cellular Immunology, v. 12, n. 543, p. 1-3, 2021.
MCMILLIAN, M. Pasteur's Quadrant and Vaccines. The Yale Journal of Biology and Medicine, v. 87, n. 3, p. 227-232, 2014.
MEANS, B. et al. Tracking public engagement in science: Measuring changes in knowledge, attitudes, and behaviors related to the COVID-19 pandemic. PS: Political Science & Politics, v. 53, n. 4, p. 547–553, 2020. Disponível em: https://doi.org/10.1017/S1049096520001038. Acesso em: 03 de setembro de 2021.
OMER, S. B. et al. Vaccine hesitancy, vaccine refusal, and the anti-vaccine movement: Influence, impact, and implications. Expert Review of Vaccines, v. 19, n. 11, p. 991-997, Nov. 2020.
ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS). Resumo das vacinas: Difteria, tétano e tosse convulsa (vacina DTP). 2019. Disponível em: https://www.who.int/immunization/programmes_systems/interventions/tripartite_vaccine_field_guide/resumo_dtp/en/. Acesso em: 30 jun. 2021.
ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS). Vacinas. Disponível em: https://www.who.int/es/news-room/q-a-detail/vaccines#:~:text=Las%20vacunas%20son%20productos%20biol%C3%B3gicos,al%20organismo%20la%20enfermedad%20bajo. Acesso em: 24 de junho de 2021.
ORGANIZAÇÃO MUNDIAL DA SAÚDE. COVID-19 Vaccines. Disponível em: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines. Acesso em: fev. 2023.
ORGANIZAÇÃO MUNDIAL DA SAÚDE. Vacinação. Disponível em: https://www.who.int/topics/vaccines/pt/. Acesso em: 03 de setembro de 2021.
ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS). Timeline: WHO response COVID-19. Geneva: WHO; 2019.
ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS). Vaccines. Disponível em: https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1. Acesso em: 02 jul. 2021.
PRAKASH, S. et al. Challenges and advances in the development of DNA vaccines. Annual Review of Pharmacology and Toxicology, v. 58, n. 1, p. 185-214, 2018.
POLACK, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, v. 383, n. 27, p. 2603-2615, 2020.
RICHARDS, K. et al. Vaccine types and terminology. Clinical Microbiology Reviews, v. 32, n. 4, 2019.
SHERIDAN, A. D. et al. Addressing Vaccine Hesitancy for COVID-19 and Future Vaccines. The American Journal of Tropical Medicine and Hygiene, v. 103, n. 4, p. 1397–1409, out. 2020. DOI: 10.4269/ajtmh.20-0816.
SOCIEDADE BRASILEIRA DE IMUNIZAÇÕES (SBIm). Importância da Vacinação. Disponível em: https://sbim.org.br/vacinacao/importancia-da-vacinacao/. Acesso em: 02 jul. 2021.
TAKAHASHI, Y. et al. Development and clinical application of vaccines and therapeutic agents using nucleic acids. Human Cell, v. 35, n. 4, p. 768-785, 2022.
UNICEF. How vaccines are developed and approved. Disponível em: https://www.unicef.org/immunization/how-vaccines-are-developed-and-approved. Acesso em: 24 de junho de 2021.
VANDERMEER, M. L. Vaccines in Modern Medicine. In: ABC OF CLINICAL GENETICS. John Wiley & Sons, 2013. Cap. 22, p. 114-120.
VENKATRAMAN, N. et al. The COVID-19 Vaccines and Their Safety: A Systematic Review of the Literature. Plastic and Reconstructive Surgery, v. 147, n. 3S, p. 69S-78S, 2021.
VOYSEY, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 2021 397(10269), 99-111.
WANG, Y. et al. Advances and prospects of nanotechnology in nucleic acid-based cancer therapy. Cancer Letters, v. 516, n. 1, p. 83-98, 2021.
WARDLE, C.; DERAKHSHAN, N. Information Disorder: Toward an interdisciplinary framework for research and policy making. Council of Europe report, 2017. Disponível em: https://rm.coe.int/information-disorder-toward-an-interdisciplinary-framework-for-resear/168076277c. Acesso em: 03 de setembro de 2021.
XIAO, M. et al. The status and trends of nucleic acid vaccine and its application prospects. Biomedicine & Pharmacotherapy, v. 130, p. 110760, 2020.
ZHANG, C. et al. Development and challenges of mRNA-based prophylactic vaccines for COVID-19. Science China Life Sciences, v. 63, n. 4, p. 487-498, 2020.
